Vivos Therapeutics, Inc. (VVOS)
NASDAQ (CM) NASDAQ (CM) Primary 
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Vivos Therapeutics (VVOS) Upgraded to Buy: Here's What You Should Know
Vivos Therapeutics (VVOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript
Vivos Therapeutics, Inc. (VVOS) Discusses Strategic Business Model Pivot and Transition in Sleep Apnea Treatment Approach Transcript
Vivos Therapeutics, Inc. (VVOS) Q3 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. ( VVOS ) Q3 2025 Earnings Call November 19, 2025 5:00 PM EST Company Participants Bradford Amman - CFO, Treasurer & Secretary R. Huntsman - Co-Founder, Chairman of the Board & CEO Conference Call Participants Lucas Ward - Ascendiant Capital Markets LLC, Research Division Robert Sassoon - Water Tower Research LLC Presentation Operator Good day, everyone, and welcome to the Vivos Third Quarter 2025 Conference Call.
Vivos Therapeutics, Inc. (VVOS) Shareholder/Analyst Call Prepared Remarks Transcript
Vivos Therapeutics, Inc. ( VVOS ) Shareholder/Analyst Call November 4, 2025 12:00 PM EST Company Participants R. Huntsman - Co-Founder, Chairman of the Board & CEO Bradford Amman - CFO, Treasurer & Secretary Jennifer Hauser Conference Call Participants Donna M.
Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q2 2025 Earnings Conference Call August 19, 2025 5:00 PM ET Company Participants Bradford K. Amman - CFO, Treasurer & Secretary R.
Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q1 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Brad Amman - CFO Kirk Huntsman - Chairman and CEO Conference Call Participants Do Kim - Water Tower Research Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone. And welcome to the Vivos Therapeutics First Quarter 2025 Earnings Call.
Vivos Therapeutics, Inc. (VVOS) Reports Q1 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $1.63 per share a year ago.
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Vivos Therapeutics (VVOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q4 2024 Earnings Conference Call March 31, 2025 5:00 PM ET Company Participants Bradford Amman - CFO, Treasurer & Secretary Kirk Huntsman - Co-Founder, Chairman & CEO Conference Call Participants Guyn Kim - Water Tower Research Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets Operator Good day, everyone, and welcome to the Vivos Therapeutics Full Year 2024 Earnings Conference Call. [Operator Instructions] This conference call is being recorded, and a replay of today's call will be available on the Investor Relations section of Vivos' website and will remain posted there for the next 30 days.
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $3.05 per share a year ago.
